Opko Health (OPK) Q2 Revenue Falls 14%
Opko Health (NASDAQ:OPK), a diversified healthcare company operating in diagnostics and pharmaceuticals, released its second quarter 2025 results on July 31, 2025. The company reported a significant revenue miss, with total GAAP revenue at $156.8 million, compared to analyst expectations of $165.7 million for Q2 2025. Its net loss per share on a GAAP basis reached $0.19, wider than estimates for a $0.11 loss and sharply higher than the prior-year figure in Q2 2025. Results were affected by lower diagnostics revenues due to asset sales, flat pharmaceutical product revenues, and the impact of a one-time charge related to a convertible note exchange in Q2 2025. Cost-cutting and divestitures helped reduce some operating losses, but overall, the quarter underscored ongoing restructuring and financial challenges for the business.
Source: Analyst estimates for the quarter provided by FactSet.
Opko Health focuses on two main business areas: pharmaceutical products and diagnostics services. Its pharmaceutical portfolio includes therapies for chronic kidney disease, hormonal disorders, and infectious diseases. Its diagnostics unit, BioReference, provides medical laboratory testing, including specialized cancer screening.
Source Fool.com
